Do you want to read an article? Please log in or register.
Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
Asthma
RECOMMENDED
Related content
RECOMMENDED
Asthma
Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Kavanagh JE, Hearn AP, Dhariwal J, Gráinne d'Ancona, Douiri A, Roxas C, Fernandes M, Green L, Thomson L, Nanzer AM, Kent BD, Jackson DJ
doi: 10.1016/j.chest.2020.08.2083.
RECOMMENDED
Asthma
Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Kayser MZ, Drick N, Milger K, Fuge J, Kneidinger N, Korn S, Buhl R, Behr J, Welte T, Suhling H
doi: 10.2147/JAA.S319572
COMMENTED
Effects of Systemic Corticosteroids on Blood Eosinophil Counts in Asthma: Real-World Data
J Asthma.
Ortega H, Llanos JP, Lafeuille MH, Duh MS, Germain G, Lejeune D, Sama S, Bell C, Hahn B
doi: 10.1080/
RECOMMENDED
Asthma
Relationship Between Benralizumab Exposure and Efficacy for Patients with Severe Eosinophilic Asthma
Clin Pharmacol Ther.
Chia YL, Yan L, Yu B, Wang B, Barker P, Goldman M, Roskos L
doi: 10.1002/cpt.
Asthma
The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies
Curr Med Res Opin.
Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X
doi: 10.1080/
RECOMMENDED
Asthma
Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Puggioni F, Brussino L, Canonica GW, Blasi F, Paggiaro P, Caminati M, Latorre M, Heffler E, Senna G, Severe Asthma Network in Italy (SANI) group.
doi: 10.2147/JAA.S274245
Asthma
Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study
J Asthma.
Albers FC, Müllerová H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES, Cockle SM, Suruki RY
doi: 10.1080/02770903.
RECOMMENDED
Asthma
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison
J Allergy Clin Immunol.
Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ, Gunsoy NB
doi: 10.1016/j.jaci.2018.08.031.
RECOMMENDED
Asthma
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
Lancet Respir Med.
Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators
doi: 10.1016/S2213-2600